Biomarkers Evaluation and Effect of Mepolizumab on Lower and Upper Airways Inflammation in Severe Refractory Eosinophilic Asthma and Nasal Polyposis
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma; Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- 01 Dec 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2024.
- 01 Dec 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Nov 2024.
- 20 Dec 2021 Status changed from not yet recruiting to recruiting.